OBIO today
$6.15+$0.14 (+2.33%)close Nov 12, 2026Trend
DailyDowntrend (starting)
4 hourStrong Bullish
1 hourStrong Bullish
15 minStrong Bullish
5 minStrong Bullish
Daily trend turns up above $6.50
Key levels
Resistance$7.04
Resistance$6.16
Support$5.39
Support$4.71
Latest news & SEC filings
EarningsOrchestra BioMed Posts Q3 2026 Results, Business Update
EarningsOrchestra BioMed posts smaller quarterly loss but revenue falls short
All OBIO news →About Orchestra BioMed
Orchestra BioMed is a biomedical innovation company that develops therapeutic product candidates through partnerships with medical device makers. Its lead programs are AVIM Therapy, a bioelectronic treatment for high blood pressure delivered through cardiac pacemakers, and Virtue SAB, a drug-coated balloon for treating diseased arteries. It has a collaboration with Medtronic for AVIM Therapy and runs clinical trials in the United States and other countries.
Based on the company's 10-K filed Mar 12, 2026.
Nasdaq · Healthcare
Orchestra BioMed Holdings, Inc. (OBIO)
What Is the Price Target for OBIO?
SEPT Low Target
$10.00
SEPT Mid Target
$10.00
SEPT High Target
$13.00
Analyst Consensus
$10.00
Is OBIO a Buy or Sell Right Now?
Thesis
- •Revenue growing 1169.2% YoY with ACCELERATING trend — accelerating momentum.
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for OBIO.
Start Free Trial →Is OBIO Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$8.52
24
Moat Score
NONE
5/9
Piotroski Score
-1.5
Altman Z-Score
What Is Smart Money Doing with OBIO?
Insider Signal
BUYING
9 buys / 3 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Fain Eric S | director | Buy | 20,000 | $100K | Nov 9, 2026 |
| Pacitti David | director | Buy | 20,000 | $100K | Nov 9, 2026 |
| Hochman David P | director officer | Buy | 5,000 | $25K | Nov 9, 2026 |
| Taylor Andrew Lawrence | officer | Buy | 1,000 | $5K | Nov 9, 2026 |
| RTW INVESTMENTS, LP | 10% owner | Buy | 1,200,000 | $6.0M | Nov 9, 2026 |
| Sherman Darren | director officer | Sale | 15,000 | $86K | Nov 2, 2026 |
| Hochman David P | director officer | Sale | 3,283 | $19K | Sep 10, 2026 |
| Hochman David P | director officer | Buy | 10,000 | $48K | Sep 3, 2026 |
| Sherman Darren | director officer | Sale | 15,000 | $74K | Sep 1, 2026 |
| Taylor Andrew Lawrence | officer | Sale | 3,076 | $16K | Aug 26, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →OBIO Growth Story
Revenue YoY
1169.2%
3yr Revenue CAGR
111.6%
EPS Growth YoY
33.13%
FCF Growth YoY
2.7%
Revenue Trend
ACCELERATING
Dark Pool Trades for OBIO
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for OBIO, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:12 | $6.15 | 1,847 | $$11K | MIDPOINT |
| 21:00:12 | $6.15 | 1,900 | $$12K | MIDPOINT |
| 20:59:06 | $6.14 | 4,821 | $$30K | MIDPOINT |
| 20:58:41 | $6.15 | 2,000 | $$12K | SELL |
| 20:50:51 | $6.04 | 1,500 | $$9K | MIDPOINT |
5 dark pool trades shown · $$74K preview volume
Real-time institutional flow, block trades, and net positioning
What Traders Are Saying About OBIO
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for OBIO. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Smart Money Moves $OBIO — Fain Eric S | Sale $100K $OBIO — Pacitti David | Sale $100K $OBIO — Hochman David P | Sale $25K $OBIO — Taylor Andrew Lawrence | Sale $5K $LUCK — Young John Alan | Sale $28K
Join 3,500+ traders discussing OBIO in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Orchestra BioMed Holdings, Inc. (OBIO) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →OBIO — frequently asked questions
What is OBIO stock price today?
Orchestra BioMed Holdings, Inc. (OBIO) is at $6.15, up 2.33% (+$0.14) at the Nov 12, 2026 close.
Why is OBIO stock moving today?
Latest OBIO news — Nov 10, 2026: Orchestra BioMed Posts Q3 2026 Results, Business Update · Nov 10, 2026: Orchestra BioMed posts smaller quarterly loss but revenue falls short
What is the OBIO price target?
The average analyst price target for OBIO is $10.00, ranging from $10 to $13, based on 4 analysts. Latest: BTIG upgrade on Sep 10, 2026.
What do analysts rate OBIO?
Analyst ratings for OBIO: 2 Buy, 3 Hold, 0 Sell — consensus Hold.
Did OBIO beat earnings?
OBIO last reported on Aug 11, 2026: EPS -$0.38 vs -$0.39 expected — a beat of 3.1%.
Does OBIO pay a dividend?
OBIO does not currently pay a dividend.
What are OBIO support and resistance levels?
Support: $5.39, $4.71, $4.20. Resistance: $6.16, $7.04, $7.71.
What are insiders doing with OBIO?
Insider activity: BUYING, 9 buys and 3 sells in the last 90 days.
What is the latest news on OBIO?
Nov 10, 2026: Orchestra BioMed Posts Q3 2026 Results, Business Update · Nov 10, 2026: Orchestra BioMed posts smaller quarterly loss but revenue falls short